Document


AGILENT TECHNOLOGIES, INC.
LIFE SCIENCES AND APPLIED MARKETS SEGMENT
(Unaudited)

All periods below were recast to reflect the movement of the Cell Analysis division to our Diagnostics and Genomics business segment from our Life Sciences and Applied Markets business segment.

(In millions, except margins data)		FY23
		Q1			Q2			Q3			Q4			Total

	Revenue	$	943		$	874		$	854		$	839		$	3,510
	Gross margin %	61.5		%	59.8		%	60.1		%	59.5		%	60.3		%
	Research and development expenses	$	67		$	69		$	62		$	64		$	262
	Selling, general and administrative expenses	$	213		$	210		$	186		$	196		$	805
	Income from operations	$	300		$	244		$	265		$	240		$	1,049
	Operating margin %	31.8		%	27.9		%	31.0		%	28.6		%	29.9		%


		FY22
		Q1			Q2			Q3			Q4			Total

	Revenue	$	900		$	799		$	921		$	1,010		$	3,630
	Gross margin %	60.5		%	58.9		%	60.4		%	60.6		%	60.1		%
	Research and development expenses	$	66		$	63		$	64		$	64		$	257
	Selling, general and administrative expenses	$	207		$	204		$	207		$	211		$	829
	Income from operations	$	271		$	204		$	285		$	337		$	1,097
	Operating margin %	30.1		%	25.5		%	31.0		%	33.3		%	30.2		%


		FY21
		Q1			Q2			Q3			Q4			Total

	Revenue	$	835		$	797		$	811		$	861		$	3,304
	Gross margin %	60.0		%	59.5		%	60.1		%	59.3		%	59.7		%
	Research and development expenses	$	59		$	62		$	60		$	63		$	244
	Selling, general and administrative expenses	$	202		$	209		$	203		$	206		$	820
	Income from operations	$	240		$	203		$	224		$	242		$	909
	Operating margin %	28.7		%	25.5		%	27.7		%	28.1		%	27.5		%

Income from operations reflect the results of our reportable segments under Agilent's management reporting system which are not necessarily in conformity with GAAP financial measures. Income from operations of our reporting segments exclude, among other things, charges related to restructuring and other related costs, asset impairments, amortization of intangibles, transformational initiatives, acquisition and integration costs, business exit and divestiture costs, special compliance costs and change in fair value of contingent consideration.

Readers are reminded that non-GAAP numbers are merely a supplement to, and not a replacement for, GAAP financial measures. They should be read in conjunction with the GAAP financial measures. It should be noted as well that our non-GAAP information may be different from the non-GAAP information provided by other companies.


AGILENT TECHNOLOGIES, INC.
DIAGNOSTICS AND GENOMICS SEGMENT
(Unaudited)

All periods below were recast to reflect the movement of the Cell Analysis division to our Diagnostics and Genomics business segment from our Life Sciences and Applied Markets business segment.

(In millions, except margins data)		FY23
		Q1			Q2			Q3			Q4			Total

	Revenue	$	432		$	456		$	422		$	445		$	1,755
	Gross margin %	52.6		%	53.7		%	53.5		%	53.7		%	53.4		%
	Research and development expenses	$	47		$	48		$	38		$	44		$	177
	Selling, general and administrative expenses	$	107		$	104		$	92		$	94		$	397
	Income from operations	$	73		$	93		$	96		$	101		$	363
	Operating margin %	16.9		%	20.5		%	22.7		%	22.7		%	20.7		%


		FY22
		Q1			Q2			Q3			Q4			Total

	Revenue	$	415		$	455		$	438		$	458		$	1,766
	Gross margin %	54.2		%	56.7		%	55.8		%	53.1		%	55.0		%
	Research and development expenses	$	42		$	44		$	43		$	45		$	174
	Selling, general and administrative expenses	$	104		$	99		$	103		$	101		$	407
	Income from operations	$	79		$	115		$	99		$	97		$	390
	Operating margin %	19.0		%	25.4		%	22.6		%	21.2		%	22.1		%


		FY21
		Q1			Q2			Q3			Q4			Total

	Revenue	$	382		$	399		$	432		$	442		$	1,655
	Gross margin %	54.4		%	55.7		%	55.5		%	55.4		%	55.3		%
	Research and development expenses	$	35		$	37		$	40		$	44		$	156
	Selling, general and administrative expenses	$	93		$	93		$	96		$	96		$	378
	Income from operations	$	80		$	92		$	104		$	105		$	381
	Operating margin %	20.8		%	23.1		%	24.1		%	23.8		%	23.0		%


AGILENT TECHNOLOGIES, INC.
AGILENT CROSSLAB SEGMENT
(Unaudited)

No change. Included to show our business segments structure in its entirety.

(In millions, except margins data)		FY23
		Q1			Q2			Q3			Q4			Total

	Revenue	$	381		$	387		$	396		$	404		$	1,568
	Gross margin %	48.5		%	47.0		%	50.9		%	50.4		%	49.3		%
	Research and development expenses	$	9		$	8		$	8		$	8		$	33
	Selling, general and administrative expenses	$	73		$	71		$	65		$	67		$	276
	Income from operations	$	103		$	103		$	129		$	128		$	463
	Operating margin %	27.0		%	26.6		%	32.7		%	31.7		%	29.5		%


		FY22
		Q1			Q2			Q3			Q4			Total

	Revenue	$	359		$	353		$	359		$	381		$	1,452
	Gross margin %	47.5		%	47.1		%	47.0		%	48.6		%	47.6		%
	Research and development expenses	$	8		$	7		$	8		$	9		$	32
	Selling, general and administrative expenses	$	72		$	72		$	72		$	72		$	288
	Income from operations	$	91		$	87		$	88		$	104		$	370
	Operating margin %	25.2		%	24.6		%	24.6		%	27.4		%	25.5		%


		FY21
		Q1			Q2			Q3			Q4			Total

	Revenue	$	331		$	329		$	343		$	357		$	1,360
	Gross margin %	46.8		%	45.3		%	46.6		%	48.3		%	46.8		%
	Research and development expenses	$	9		$	8		$	9		$	8		$	34
	Selling, general and administrative expenses	$	70		$	72		$	67		$	70		$	279
	Income from operations	$	76		$	69		$	84		$	94		$	323
	Operating margin %	23.1		%	21.0		%	24.4		%	26.3		%	23.8		%